The inhibitory effect of DEX in cerebral ischemia-induced TRPM2 and TRPV1 activation should be considered a potential pharmacological target for itching caused by cerebral ischemia-mediated activation of pain and brain injuries. The gene discussed is TRPV1; the disease is Cerebral ischemia.